<DOC>
	<DOC>NCT00664859</DOC>
	<brief_summary>The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia</brief_summary>
	<brief_title>12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia</brief_title>
	<detailed_description>POPULATION: Subjects with mixed dyslipidemia (non-HDL cholesterol &gt; 130 mg/dL and TG ≥ 150 mg/dL and ≤ 500 mg/dL) who completed the double-blind study (LCP-AtorFen-2001; NCT00504829), met the enrollment criteria (all of the inclusion criteria and none of the exclusion criteria), and elected to enter the open-label extension study. STUDY DESIGN AND DURATION: This is a 52-week, open-label, single-treatment arm with 8 visits (Weeks 0, 4, 8, 12, 24, 36, 48 and 52). A maximum of approximately 200 subjects will enter this open-label safety and efficacy extension study from the LCP AtorFen-2001 double-blind study. All subjects enrolled in this study will receive open-label LCP-AtorFen combination therapy. Visit 1 of the extension study corresponds to the last visit of the double-blind study (Visit 6 or Week 12).</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1. Subject has successfully completed the doubleblind study (LCPAtorFen2001; NCT00504829). 2. Subject has confirmed his or her willingness to participate in this study after being informed of all aspects of the study by voluntarily signing and dating an informed consent form in accordance with Good Clinical Practice (GCP). 1. Study drug compliance &lt;70% in the doubleblind study. 2. Any ongoing serious adverse event, or any ongoing nonserious moderate or severe adverse event from the doubleblind study that is rated as possibly, probably or definitely related to study drug. 3. Resting blood pressure &gt;/=160 mm Hg systolic and/or &gt;/=100 mm Hg diastolic. 4. Symptoms of unexplained muscle pain, tenderness or weakness (i.e., signs indicative of possible myopathy), or any diagnosis of myopathy or rhabdomyolysis. 5. Any clinically significant change in physical exam or electrocardiogram from Visit 2 to Visit 6 of the doubleblind study. 6. Any clinically significant change from Visit 1 to Visit 6 of the doubleblind study in medical history including, but not limited to: a diagnosis of insulindependent diabetes mellitus (DM); poorly controlled DM; poorly controlled hypertension; significant renal, pulmonary, hepatic, biliary, or gastrointestinal disease; cancer (except nonmelanoma skin cancer); and epilepsy. 7. Unwilling to abstain from medications, supplements, ingredients and herbal therapies that were excluded in the doubleblind study and continue to be excluded in the openlabel study. 8. Women who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential (not surgically sterilized between menarche and menopause) who are not using a medically approved method of contraception. 9. Other exclusion conditions might apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>LCP-AtorFen</keyword>
	<keyword>Non-HDL cholesterol</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>HDL cholesterol</keyword>
	<keyword>LDL cholesterol</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>